

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

VOLUNTARY ANNOUNCEMENT

STRATEGIC COOPERATION FRAMEWORK AGREEMENT

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on 20 December 2023, Blooming Faith Development Limited (“**Blooming Faith**”, a wholly-owned subsidiary of the Company) entered into a strategic cooperation framework agreement (the “**Framework Agreement**”) with 深圳市怡亞通醫療供應鏈管理有限公司 (Shenzhen Eternal Asia Medical Supply Management Co., Ltd.*) (“**Eternal Asia**”) to launch strategic cooperation on the followings:

1. The Company shall authorise Eternal Asia to act as the cooperative partner of the longevity biological product series sold by the Company for a term of one year.
2. Eternal Asia shall be responsible for the distribution of the longevity products sold by the Company and shall purchase approximately HK\$10 million worth of longevity products being run and marketed by the Company or its subsidiaries.

INFORMATION OF ETERNAL ASIA

Eternal Asia is committed to transforming the scattered, chaotic and disorderly operating pattern of products agency and distribution and circulation in traditional pharmaceutical enterprises. Through the concept of integration and resource-sharing to establish a new business model of pharmaceuticals distribution characterised by delayering, sharing and decentralisation, and achieve rapid direct end-to-end supply.

REASONS FOR AND BENEFITS OF THE FRAMEWORK AGREEMENT

The Board believes that the Framework Agreement will further expand the Group's existing sales network and business of longevity biological products, and further broaden the revenue base of its longevity biological products to bring stable and sustainable growth in revenue to the Group in the long run, thus further improving the Group's footprint in longevity science.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 20 December 2023

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Yan Yifan (*Chief Executive Officer*)
Mr. Li Xiaoshuang
Ms. Cao Xie Qiong

Independent Non-executive Directors

Mr. Lee See Barry
Mr. Wang Ning
Prof. Huang Cibo

Non-executive Directors

Dr. He Yiwu
Mr. Lyu Changsheng

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.

* *For identification purpose only*